Short-term intraocular pressure changes following intravitreal injections of aflibercept 8mg versus 2mg: A prospective comparative study
- 27 July 2026
- journal article
- research article
- Published by SAGE Publications in European Journal of Ophthalmology
Abstract
Purpose: The increased injection volume of aflibercept 8 mg (0.07 ml versus 0.05 ml) raises theoretical concerns regarding intraocular pressure (IOP) effects. This study evaluated acute IOP dynamics following aflibercept 8 mg compared to aflibercept 2 mg and identified predictive factors for pressure elevation. Methods: 140 eyes of 127 patients receiving aflibercept 8 mg (70 eyes) or 2 mg (70 eyes) between January-December 2025 were included. IOP was measured at baseline (T0), immediately post-injection (T1), and 30 min post-injection (T2). Linear mixed-effects models assessed the effects of time, treatment group, and time-by-treatment interactions. Multivariable mixed-effects logistic regression was used to identify predictors of IOP >21mmHg and IOP elevation >5mmHg at T2. Results: Both formulations produced significant IOP elevations from baseline at T1 and T2 ( p < 0.001 within each group). Mean IOP increased from 14.0 mmHg to 39.3 mmHg (aflibercept 2 mg) and 14.5 mmHg to 39.3 mmHg (aflibercept 8 mg) immediately post-injection, with near-complete resolution by 30 min (16.9 vs 17.7 mmHg). No significant between-group differences were identified at any timepoint. Pre-existing glaucoma/OHT was the only consistent independent predictor of both IOP >21 mmHg (OR 3.00–3.31, p = 0.024–0.038) and IOP elevation >5 mmHg from baseline (OR 10.45–11.75, p < 0.001) at T2; aflibercept formulation was not associated with either outcome. No injection required paracentesis. Conclusion: Aflibercept 8 mg demonstrates comparable IOP dynamics to aflibercept 2 mg. Glaucoma/OHT represents the strongest predictor of early pressure elevation, warranting enhanced monitoring.Keywords
This publication has 39 references indexed in Scilit:
- Comparison of intraocular pressure measured by iCare tonometers and Goldmann applanation tonometerCanadian Journal of Ophthalmology, 2022
- Long-term effect of intravitreal ranibizumab therapy on retinal nerve fiber layer in eyes with exudative age-related macular degenerationGraefe's Archive for Clinical and Experimental Ophthalmology, 2019
- Incidence of Presumed Silicone Oil Droplets in the Vitreous Cavity After Intravitreal Bevacizumab Injection With Insulin SyringesJAMA Ophthalmology, 2017
- Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective studyGraefe's Archive for Clinical and Experimental Ophthalmology, 2017
- Bevacizumab clearance through the iridocorneal angle following intravitreal injection in a rat modelExperimental Eye Research, 2016
- Repeated Intravitreous Ranibizumab Injections for Diabetic Macular Edema and the Risk of Sustained Elevation of Intraocular Pressure or the Need for Ocular Hypotensive TreatmentJAMA Ophthalmology, 2015
- Intraocular Pressure in Eyes Receiving Monthly Ranibizumab in 2 Pivotal Age-Related Macular Degeneration Clinical TrialsOphthalmology, 2014
- Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degenerationGraefe's Archive for Clinical and Experimental Ophthalmology, 2012
- Short-term Intraocular Pressure Changes Immediately After Intravitreal Injections of Anti–Vascular Endothelial Growth Factor AgentsAmerican Journal of Ophthalmology, 2008
- Short-term Course of Intraocular Pressure after Intravitreal Injection of Triamcinolone AcetonideOphthalmology, 2006